Westfield Capital Management
ACAD icon

Westfield Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Westfield Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-545,976
Closed -$26.5M – 236
2020
Q2 		$26.5M Buy
545,976
+36,091
+7% +$1.73M 0.18% 143
2020
Q1 		$21.5M Buy
+509,885
New +$21M 0.19% 135
2017
Q2 		– Sell
-238,694
Closed -$8.21M – 251
2017
Q1 		$8.21M Buy
+238,694
New +$8.43M 0.07% 215
2016
Q2 		– Sell
-13,450
Closed -$376K – 258
2016
Q1 		$376K Sell
13,450
-1,466,054
-99% -$32M ﹤0.01% 241
2015
Q4 		$52.7M Buy
+1,479,504
New +$52.1M 0.36% 94
2014
Q3 		– Sell
-2,308,261
Closed -$52.1M – 300
2014
Q2 		$52.1M Sell
2,308,261
-39,150
-2% -$817K 0.31% 107
2014
Q1 		$57.1M Sell
2,347,411
-623,630
-21% -$15.8M 0.34% 102
2013
Q4 		$74.2M Buy
2,971,041
+910,490
+44% +$21.5M 0.44% 74
2013
Q3 		$56.6M Buy
+2,060,551
New +$43.1M 0.36% 96

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Westfield Capital Management's ACAD Position: Q3 2020 in Review

Westfield Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q3 2020, closing a stake of 545,976 shares — an estimated $26.5M sold.

Westfield Capital Management first reported a position in ACAD in Q3 2013 and held it in 9 quarters. The position peaked at $74.2M in Q4 2013. 267 funds tracked by Wall St. Rank hold ACAD as of Q3 2020.

  • Westfield Capital Management reported no remaining Acadia Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Westfield Capital Management sold 545,976 Acadia Pharmaceuticals shares in Q3 2020, an estimated $26.5M.
  • Westfield Capital Management first reported a position in Acadia Pharmaceuticals in Q3 2013 and held it in 9 quarters.
  • Westfield Capital Management's Acadia Pharmaceuticals position peaked at $74.2M in Q4 2013.
  • 267 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2020.

Based on Westfield Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.